The SGLT2 inhibitor was superior to other antidiabetic treatments, decreasing the risk of HF-related hospitalization rates by 39%, all-cause mortality by 51% and combined HF hospitalizations and all-cause death by 46% [72]. Here, SLC5A2 is linked to hydrops fetalis.